Stock Taper
SCREENER COMPARE ANY 2 STOCKS
COLL
COLLEGIUM PHARMACEUTICAL, INC.
NASDAQ
$25.35
▼ DOWN 4.12% (-1.09)

KEY STATISTICS

Market Cap$822.20 M
52w High$50.79
52w Low$25.16
Dividend Yield—
Frequency—
P/E3.18
Volume813.95K
Shares Out.32.43M

COMPANY

LEADERSHIP

Vikram Karnani
CHIEF EXECUTIVE
Vikram Karnani

COMPENSATION 2026

Salary$875,000
Stock Awards$0
Incentive Plan Pay$835,406
All Other Comp.$5,440
Total$1,715,846

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 7, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
423

PRICE TARGET

Target High$48.00
Target Low$48.00
Target Median$48.00
Target Consensus$48.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$218.47M
NOV
5
THU

PRICE

$25.35 ▼ DOWN 4.12% (−$1.09)
$25.50$26.00$26.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM25.35

About Collegium Pharmaceutical, Inc.

https://www.collegiumpharma.com ↗

Collegium Pharmaceutical, Inc. is a Massachusetts-based specialty pharma company developing and commercializing pain management medicines like Xtampza ER and Nucynta formulations.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT COLLEGIUM PHARMACEUTICAL, INC. IS KNOWN FOR

Jornay PM
Jornay PM

Jornay PM, Collegium Pharmaceutical's leading ADHD treatment for patients 6 and older, is a CNS stimulant driving significant growth and expanding the company's presence in neuropsychiatry.

COMPETITORS

COMPETITOR
AYTU COMPARE
JNJ COMPARE
PFE COMPARE
SUPN COMPARE
TAK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Belbuca$58.26M $59.14M ▲$52.65M ▼$57.67M ▲
Xtampza ER$50.48M $48.58M ▼$50.77M ▲$45.01M ▼
Nucynta ER$22.81M $18.54M ▼$18.23M ▼$15.72M ▼
Nucynta IR$31.99M $29.41M ▼$26.08M ▼$14.36M ▼
Symproic$4.03M — $4.19M ▲$3.02M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
204
LISTED HERE
26
RANKED BY POSITION SIZE
AFTY
1.38% · 2.5M
XUU.TO
0.00% · 2.0M
VTI
0.00% · 978.0K
AVUV
0.03% · 415.3K
PJP
1.93% · 391.4K
SPSM
0.05% · 303.2K
USVM
0.24% · 162.7K
SCHA
0.02% · 155.3K
FYC
0.28% · 154.4K
JSMD
0.33% · 130.8K
DFMC
0.04% · 116.7K
SURI
2.36% · 80.9K
FSMD
0.08% · 80.3K
MGMT
1.10% · 75.7K
PSC
0.07% · 73.8K
GSSC
0.10% · 43.1K
SMIZ
0.39% · 42.2K
EES
0.16% · 41.5K
SIXS
0.70% · 38.3K
HAPS
0.56% · 37.7K
JPSE
0.16% · 36.3K
NUSC
0.06% · 34.6K
XRS2.DE
0.03% · 30.1K
DSMC
0.39% · 22.4K
RSSL
0.03% · 15.6K
BFOR
0.16% · 14.9K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
93.22%
HOLDERS
390
TOP 12 OF 390 · RANKED BY POSITION SIZE
Blackrock Inc.
5.8M sh · $186.55M
Blackrock, Inc.
5.4M sh · $196.97M
Rubric Capital Management LP
2.8M sh · $98.9M
Eventide Asset Management, LLC
2.4M sh · $83.65M
Vanguard Group Inc
2.3M sh · $104.46M
Invesco Ltd.
1.9M sh · $68.15M
Janus Henderson Group Plc
1.8M sh · $60.36M
Fuller & Thaler Asset Management, Inc.
1.6M sh · $59.11M
Principal Financial Group Inc
1.6M sh · $59.09M
Renaissance Technologies LLC
1.6M sh · $74.88M
State Street Corp
1.5M sh · $55.35M
Massachusetts Financial Services Co /Ma/
1.4M sh · $50.88M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity4
Return On Assets4
Debt To Equity1
Price To Earnings2
Price To Book2
Overall Score3

INSIDER TRADES

★
DIRECTOR
SANTINI GINO
Purchase · 8.7K shares
2026-06-08
★
DIRECTOR
SANTINI GINO
Sale · 8.7K shares
2026-06-08
★
DIRECTOR
Freund John Gordon
Sale · 20 shares
2026-05-18
★
DIRECTOR
Paya Carlos V
Purchase · 8.7K shares
2026-05-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 1
NEUTRAL 1
5 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Piper Sandler NEUTRAL Needham BUY HC Wainwright & Co. BUY Truist Securities BUY

SECTORS PEERS

PEERPRICE
PLSE$47.57COMPARE
ATAI$7.29COMPARE
NKTR$72.52COMPARE
INVA$20.97COMPARE
CRON$3.38COMPARE
GDRX$3.53COMPARE
PCRX$25.76COMPARE
AMPH$22.01COMPARE